VMI
SPRO icon

VHCP Management II’s Spero Therapeutics SPRO Stock Holding History

VHCP Management II’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$4.56M Hold
474,015
– – 1.2% 10
2019
Q3 		$5.03M Hold
474,015
– – 1.92% 10
2019
Q2 		$5.46M Hold
474,015
– – 1.72% 13
2019
Q1 		$6.07M Hold
474,015
– – 1.78% 13
2018
Q4 		$2.92M Hold
474,015
– – 1.25% 13
2018
Q3 		$4.98M Hold
474,015
– – 1.33% 14
2018
Q2 		$6.95M Sell
474,015
-11,600
-2% -$148K 2.08% 13
2018
Q1 		$6.92M Hold
485,615
– – 1.67% 15
2017
Q4 		$5.71M Buy
+485,615
New +$5.96M 1.37% 13

Other funds holding SPRO

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

VHCP Management II's SPRO Position: Q4 2019 in Review

VHCP Management II held its Spero Therapeutics (SPRO) position steady in Q4 2019 at 474,015 shares worth $4.56M. The position accounts for 1.2% of the portfolio, ranked #10.

VHCP Management II first reported a position in SPRO in Q4 2017 and has held it in 9 quarters since. The position peaked at $6.95M in Q2 2018. 61 funds tracked by Wall St. Rank hold SPRO as of Q4 2019.

  • VHCP Management II held 474,015 shares of Spero Therapeutics worth $4.56M as of Q4 2019.
  • VHCP Management II left its Spero Therapeutics share count unchanged in Q4 2019.
  • Spero Therapeutics made up 1.2% of VHCP Management II's portfolio in Q4 2019, its #10 holding.
  • VHCP Management II first reported a position in Spero Therapeutics in Q4 2017 and has held it in 9 quarters since.
  • VHCP Management II's Spero Therapeutics position peaked at $6.95M in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2019.

Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.